Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer

Global cancer statistics

Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER

Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730

Mechanisms of resistance to EGFR-targeted drugs: lung cancer

Morgillo, F., Della Corte, C. M., Fasano, M., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000060 · Cited by 476

Third generation EGFR TKIs: current data and future directions

Tan, C., Kumarakulasinghe, N. B., Huang, Y., Ang, Y. L. E., Choo, J. R.-E., Goh, B.-C., & Soo, R. A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0778-0 · Cited by 322

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Li, Y.-S., Jiang, B., Yang, J., Tu, H., Zhou, Q. H., Guo, W., Yan, H., & Wu, Y.-L. L. C. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.029 · Cited by 317

Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies

Lim, S. M., Syn, N. L. X., Cho, B. C., & Soo, R. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.006 · Cited by 293

Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities

Zubair, T., & Bandyopadhyay, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032651 · Cited by 248

Long non-coding RNAs in anti-cancer drug resistance

Chen, Q.-N., Wei, C., Wang, Z., & Sun, M. (2016) · Oncotarget · doi:10.18632/oncotarget.12461 · Cited by 208

Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism

Abourehab, M. A. S., Alqahtani, A. M., Youssif, B. G. M., & Gouda, A. M. (2021) · Molecules · doi:10.3390/molecules26216677 · Cited by 211

Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders

Cheng, M., Yu, X., Lu, K. J., Xie, L., Wang, L., Meng, F., Han, X., Chen, X., Liu, J., Xiong, Y., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01566 · Cited by 197

Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance

Patel, H., Pawara, R., Ansari, A., & Surana, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.027 · Cited by 170

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156

High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma

Jin, C., Du, L., Nuerlan, A.-H., Wang, X., Yang, Y., & Guo, R. (2020) · Aging · doi:10.18632/aging.202292 · Cited by 134

Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances

Ali, E. M. H., Abdel‐Maksoud, M. S., & Oh, C. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.044 · Cited by 125

NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma

Tiedje, V., Ting, S. C., Herold, T., Synoracki, S., Latteyer, S., Moeller, L. C., Zwanziger, D., Stuschke, M., Fuehrer, D., & Schmid, K. W. (2017) · Oncotarget · doi:10.18632/oncotarget.17300 · Cited by 88

The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV

Hemmat, N., Asadzadeh, Z., Ahangar, N. K., Alemohammad, H., Najafzadeh, B., Derakhshani, A., Baghbanzadeh, A., Baghi, H. B., Javadrashid, D., Najafi, S., et al. (2021) · Archives of Virology · doi:10.1007/s00705-021-04958-7 · Cited by 81

Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors

Dorantes-Heredia, R., Ruiz-Morales, J. M., & Cano-García, F. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.07.10 · Cited by 73

MicroRNA‐mediated drug resistance in ovarian cancer

Mihanfar, A., Fattahi, A., & Nejabati, H. R. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26060 · Cited by 72

Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity

Xie, X., Baird, D., Bowen, K. E., Čápka, V., Chen, J., Chenail, G., Cho, Y., Dooley, J., Farsidjani, A., Fortin, P. D., et al. (2017) · Structure · doi:10.1016/j.str.2016.12.017 · Cited by 70

High throughput scaffold-based 3D micro-tumor array for efficient drug screening and chemosensitivity testing

Yan, X., Zhou, L., Wu, Z., Wang, X., Chen, X., Yang, F., Guo, Y., Wu, M., Chen, Y., Li, W., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.020 · Cited by 66

Management of epidermal growth factor receptor tyrosine kinase inhibitor‐related cutaneous and gastrointestinal toxicities

Aw, D. C., Tan, E. H., Chin, T. M., Lim, H. L., Lee, H. Y., & Soo, R. A. (2017) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12687 · Cited by 69

The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models.

Friese‐Hamim, M., Bladt, F., Locatelli, G., Stammberger, U. M., & Blaukat, A. (2017) · PubMed Central · doi:10.7892/boris.135350 · Cited by 62

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer

Ahluwalia, M. S., Becker, K. D., & Levy, B. P. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0572 · Cited by 60

Liquid biopsy genotyping in lung cancer: ready for clinical utility?

Huang, W.-L., Chen, Y.-L., Yang, S., Ho, C., Wei, F., Wong, D. T., Su, W., & Lin, C. (2017) · Oncotarget · doi:10.18632/oncotarget.14613 · Cited by 58

Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer

Xu, Z., & Li, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s194870 · Cited by 60

Pathologists and liquid biopsies: to be or not to be?

Hofman, P. M., & Popper, H. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-2004-z · Cited by 55

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence

Wang, X., Goldstein, D., Crowe, P. J., & Yang, J. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s94745 · Cited by 55

Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations

Masuzawa, K., Yasuda, H., Hamamoto, J., Nukaga, S., Hirano, T., Kawada, I., Naoki, K., Soejima, K., & Betsuyaku, T. (2017) · Oncotarget · doi:10.18632/oncotarget.22297 · Cited by 53

Pulsatile Erlotinib in EGFR-Positive Non–Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature

How, J., Mann, J., Laczniak, A. N., & Baggstrom, M. Q. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.01.013 · Cited by 52

Targeted Therapy in Brain Metastases: Ready for Primetime?

Venur, V. A., & Ahluwalia, M. S. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100006 · Cited by 57

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors

Liao, B.-C., Lin, C., Lee, J., & Yang, J. C. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0305-9 · Cited by 52

Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?

Gampa, G., Vaidhyanathan, S., Sarkaria, J. N., & Elmquist, W. F. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.06.008 · Cited by 48

Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis

Yan, W., Liu, Y., Li, J., Han, A., Kong, L., Yu, J., & Zhu, H. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1376-z · Cited by 48

Optimal management of EGFR -mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy

Liao, B.-C., Lin, C., Lee, J., & Yang, J. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.05.009 · Cited by 48

EGFR T790M: revealing the secrets of a gatekeeper

Ko, B., Paucar, D., & Halmos, B. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s117944 · Cited by 47

Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications

Juan, Ó., & Popat, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016687262 · Cited by 43

Treatment options for EGFR mutant NSCLC with CNS involvement—Can patients BLOOM with the use of next generation EGFR TKIs?

Tan, C., Cho, B. C., & Soo, R. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.012 · Cited by 45

Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy

Zhou, X., Shi, K., Hao, Y., Yang, C., Zha, R., Cheng, Y., & Qian, Z. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2019.06.001 · Cited by 44

Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer

Lin, S., Hsu, Y. C., Peng, Y.-H., Ke, Y., Lin, W., Sun, H.-Y., Shiao, H., Kuo, F., Chen, P.-Y., Lien, T., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00722 · Cited by 44

Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non–Small-Cell Lung Cancer

Legras, A., Barritault, M., Tallet, A., Fabre, E., Guyard, A., Rance, B., Digan, W. E., Pécuchet, N., Leprieur, E. G., Julié, C., et al. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.04.002 · Cited by 42

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors

Han, J., Lee, K. H., Kim, S., Min, Y. J., Cho, E., Lee, Y., Lee, S.-H., Kim, H. Y., Lee, G. K., Nam, B., et al. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2016.058 · Cited by 39

EGF-Induced VEGF Exerts a PI3K-Dependent Positive Feedback on ERK and AKT through VEGFR2 in Hematological In Vitro Models

Saryeddine, L., Zibara, K., Kassem, N. A., Badran, B. M., & Zein, N. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165876 · Cited by 38

Erlotinib for the treatment of brain metastases in non-small cell lung cancer

Brower, J. V., & Robins, H. I. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1165206 · Cited by 37

Clinical outcomes using carbon-ion radiotherapy and dose-volume histogram comparison between carbon-ion radiotherapy and photon therapy for T2b-4N0M0 non-small cell lung cancer—A pilot study

Shirai, K., Kawashima, M., Saitoh, J.-I., Abe, T., Fukata, K., Shigeta, Y., Irie, D., Shiba, S., Okano, N., Ohno, T., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175589 · Cited by 38

Targeting the EGFR T790M mutation in non-small-cell lung cancer

Normanno, N., Maiello, M. R., Chicchinelli, N., Iannaccone, A., Esposito, C., Cecio, R. D., D’Alessio, A., & Luca, A. D. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1272582 · Cited by 37

Decreased expression of NEDD4L contributes to NSCLC progression and metastasis

Wang, X., Duan, J., Fu, W., Yin, Z., Sheng, J., Lei, Z., & Wang, H. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.04.001 · Cited by 36

Treatment trends for patients with brain metastases: Does practice reflect the data?

Sandler, K. A., Shaverdian, N., Cook, R., Kishan, A. U., King, C. R., Yang, I., Steinberg, M. L., & Lee, P. P. (2017) · Cancer · doi:10.1002/cncr.30607 · Cited by 32

Systemic therapy for brain metastases

Venur, V. A., Karivedu, V., & Ahluwalia, M. S. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-12-811161-1.00011-6 · Cited by 32

A genome-wide comprehensive analysis of alterations in driver genes in non-small-cell lung cancer

Yi, J., Xiang, W., Li, X., Wan, L., Dong, J., & Wang, R. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000571 · Cited by 30

Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors

Romu, A., Lei, Z., Zhou, B., Chen, Z., & Korlipara, V. L. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.09.048 · Cited by 27

A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer

Gawli, C., Patil, C. R., & Patel, H. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118146 · Cited by 27

Synthesis, crystal structure and activity evaluation of novel 3,4-dihydro-1-benzoxepin-5(2 H )-one derivatives as protein–tyrosine kinase (PTK) inhibitors

Li, N., Yao, B.-R., Wang, C., Meng, Q.-G., & Hou, G. (2017) · Acta Crystallographica Section C Structural Chemistry · doi:10.1107/s2053229617015145 · Cited by 25

The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer

Yang, H., Liu, L., Zhou, C., Xiong, Y., Hu, Y., Yang, N., & Qu, J. (2019) · Medicine · doi:10.1097/md.0000000000014893 · Cited by 25

Clinical Application of Picodroplet Digital PCR Technology for Rapid Detection of EGFR T790M in Next-Generation Sequencing Libraries and DNA from Limited Tumor Samples

Borsu, L. A., Intrieri, J., Thampi, L. M., Yu, H. A., Riely, G. J., Nafa, K., Chandramohan, R., Ladanyi, M., & Arcila, M. E. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.07.004 · Cited by 22

Integrin α5 promotes migration and invasion through the FAK/STAT3/AKT signaling pathway in icotinib‑resistant non‑small cell lung cancer cells

Yang, Y., Wang, Y., Che, X., Hou, K., Wu, J., Zheng, C., Yang, C. H., Liu, Y., Hu, X., & Zhang, J. (2021) · Oncology Letters · doi:10.3892/ol.2021.12817 · Cited by 22

Regulation of cytotoxicity and apoptosis-associated pathways contributes to the enhancement of efficacy of cisplatin by baicalein adjuvant in human A549 lung cancer cells

Kiartivich, S., Wei, Y., Liu, J., Soi‐ampornkul, R., Li, M., Zhang, H., & Dong, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.5746 · Cited by 22

A Neuro-oncologist’s Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer

McGranahan, T. M., & Nagpal, S. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0466-0 · Cited by 21

LHX6 Affects Erlotinib Resistance and Migration of EGFR-Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling

Wang, Q., Liao, J., He, Z., Su, Y., Lin, D., Xu, L., Xu, H., & Lin, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s258896 · Cited by 21

Depression and inflammation among epidermal growth factor receptor (EGFR) mutant nonsmall cell lung cancer patients

McFarland, D. C., Jutagir, D. R., Rosenfeld, B. D., Pirl, W. F., Miller, A. H., BREITBART, W. S., & Nelson, C. J. (2019) · Psycho-Oncology · doi:10.1002/pon.5097 · Cited by 20

Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine

Lazaro, T. T., & Brastianos, P. K. (2017) · CNS Oncology · doi:10.2217/cns-2016-0038 · Cited by 18

Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors

Kashima, J., Okuma, Y., Miwa, M., & Hosomi, Y. (2016) · Medical Oncology · doi:10.1007/s12032-016-0843-8 · Cited by 17

Strategies to Overcome Resistance Mutations of Bruton's Tyrosine Kinase Inhibitor Ibrutinib

Liu, L., Shi, B., Wang, X., & Xiang, H. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0145 · Cited by 18

Towards Circulating-Tumor DNA-Based Precision Medicine

Hironaka‐Mitsuhashi, A., Calle, A. S., Ochiya, T., Takayama, S., & Suto, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091365 · Cited by 16

Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing

Zhao, Y., He, J. Y., Cui, J., Meng, Z.-Q., Zou, Y. L., Guo, X. S., Chen, X., Wang, X., Yan, L.-T., Han, W., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07172-x · Cited by 16

High-throughput detection of clinically targetable alterations using next-generation sequencing

Vendrell, J. A., Grand, D., Rouquette, I., Costes, V., Icher, S., Sèlves, J., Larrieux, M., Barbe, A., Brousset, P., & Solassol, J. (2017) · Oncotarget · doi:10.18632/oncotarget.15875 · Cited by 16

Combination of Radiotherapy and Targeted Agents in Brain Metastasis: An Update

Aly, Z., & Peereboom, D. M. (2016) · Current Treatment Options in Neurology · doi:10.1007/s11940-016-0416-3 · Cited by 14

Pharmacological management of relapsed/refractory NSCLC with chemical drugs

Karachaliou, N., Sosa, A. E., Barrón, F., Cao, M. G., Santarpía, M., & Rosell, R. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1285284 · Cited by 13

Accuracy of the cobas EGFR Mutation Assay in Non–small-cell Lung Cancer Compared With Three Laboratory-developed Tests

Nakamura, H., Koizumi, H., Sakai, H., Kimura, H., Miyazawa, T., Marushima, H., Saji, H., & Takagi, M. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.10.015 · Cited by 13

Noncoding RNAs and Liquid Biopsy in Lung Cancer: A Literature Review

Haranguș, A., Berindan‐Neagoe, I., Todea, D. A., Şimon, I., & Șimon, M. (2019) · Diagnostics · doi:10.3390/diagnostics9040216 · Cited by 12

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC

Kim, N. A., Hong, S., Kim, K. H., Choi, D. H., Kim, J. S., Park, K. E., Choi, J. Y., Shin, Y. K., & Jeong, S. H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020121 · Cited by 11

Determination of AZD3759 in rat plasma and brain tissue by LC–MS/MS and its application in pharmacokinetic and brain distribution studies

Xiong, S., Xue, M., Mu, Y., Deng, Z., Sun, P., & Zhou, R. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.03.056 · Cited by 10

Retrospective analysis of survival in patients with leptomeningeal carcinomatosis from lung adenocarcinoma treated with erlotinib and gefitinib

Kashima, J., Okuma, Y., Miwa, M., & Hosomi, Y. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyw206 · Cited by 9

Pyoluteorin Induces Apoptosis and Autophagy in NSCLC Cells

Fan, D., Yu, S., Yang, Y., & Qu, S. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00120 · Cited by 9

Impact of molecular alterations on quality of life and prognostic understanding over time in patients with incurable lung cancer: a multicenter, longitudinal, prospective cohort study

Kuon, J., Blasi, M., Unsöld, L., Vogt, J., Mehnert, A., Alt‐Epping, B., van Oorschot, B., Sistermanns, J., Ahlborn, M., Ritterbusch, U., et al. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06736-2 · Cited by 9

Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies

Kiriwan, D., Seetaha, S., Jiwacharoenchai, N., Tabtimmai, L., Sousa, S. F., Songtawee, N., & Choowongkomon, K. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14010 · Cited by 9

“Liquid elbows” due to afatinib administration

Zarogoulidis, P., Chinelis, P., Athanasiadou, A., Porpodis, Κ., Kallianos, A., Rapti, A., Trakada, G., Velentza, L., Huang, H., Tsiouda, T., et al. (2017) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2017.06.013 · Cited by 6

Heuristic value-based framework for lung cancer decision-making

Mambetsariev, I., Pharaon, R. R., Nam, A., Knopf, K., Djulbegović, B., Villaflor, V. M., Vokes, E. E., & Salgia, R. (2018) · Oncotarget · doi:10.18632/oncotarget.25643 · Cited by 6

Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials

Li, X., Liu, Y., Xu, Y., Ding, J., Su, Y., 何翠霞, Zhu, M., Zhao, X., Wang, Y., Shan, R., et al. (2023) · Investigational New Drugs · doi:10.1007/s10637-023-01356-5 · Cited by 5

Synthesis and preclinical evaluation of [11C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptor

Högnäsbacka, A., Poot, A. J., Plisson, C., Bergare, J., Bonsall, D. R., McCluskey, S. P., Wells, L. A., Kooijman, E. J. M., Schuit, R. C., Verlaan, M., et al. (2024) · EJNMMI Research · doi:10.1186/s13550-024-01078-6 · Cited by 5

YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFRL858R, T790M‐mutant resistance in vitro and in vivo

Zhang, Z., Zou, J., Yu, L., Luo, J., Li, Y., Tu, Z., Ren, X., Wei, H., Song, L., Lu, X., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1392 · Cited by 5

El cáncer de pulmón de células no pequeñas en la era de la medicina de precisión

Rivas, S., & Armisén, R. (2022) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2022.01.001 · Cited by 4

[Acquired Drug Resistance Mechanism of Osimertinib in the Targeted Therapy of Non-small Cell Lung Cancer].

Zhao, Z., Ni, Y., Li, L., & Xin, T. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.103.02 · Cited by 4

Synthesis and Anticancer Activity of Functionalized Thieno[2,3-d]pyrimidine Compounds and Their Triazinyl and Tetrazinyl Derivatives

El-Sofany, W. I., Osman, D. A. A., Mahran, A. M., May, E.-M. A., & El‐Sayed, W. A. (2020) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s106816202003005x · Cited by 4

Approved and Clinical Trial Third-Generation EGFR Inhibitors

Patel, H., Pawara, R. H., & Surana, S. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102661-8.00002-0 · Cited by 4

Targeted Therapy for Non-Small Cell Lung Cancer

Kim, J. S., & Kang, E. J. (2020) · Korean Journal of Medicine · doi:10.3904/kjm.2020.95.2.78 · Cited by 4

Immunotherapy and Targeted Therapies in the Treatment of Non-small Cell Lung Cancer

Nguyen‐Ngoc, T., Reck, M., Tan, D. S. W., & Peters, S. (2017) · European Oncology & Haematology · doi:10.17925/eoh.2017.13.01.35 · Cited by 4

XHL11, a novel selective EGFR inhibitor, overcomes EGFRT790M-mediated resistance in non-small cell lung cancer

Li, Y., Yu, Q.-L., Li, T.-F., Xiao, Y.-N., Zhang, L., Zhang, Q., Ren, C., & Xie, H. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174297 · Cited by 3

Comparative multi-pathway inhibition of breast cancer by micro-and nano-formulated Curcumin

Moawad, M., Altrawy, A., Nasr, G. M., Aal, W. S. A. E., Nasr, M., Eissa, M. S., & Shaker, E. S. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11506-6 · Cited by 2

Development and Validation of an LC-MS/MS Method for Quantitative Determination of EAI045, A Novel EGFR Inhibitor, in Rat Plasma

Chu, Z., Xue, M., & Xiong, S. (2019) · Current Pharmaceutical Analysis · doi:10.2174/1573412915666190206125557 · Cited by 2

Bevacizumab Combined with Icotinib Overcomes Osimertinib Resistance in a Patient of Non-Small Cell Lung Cancer

Zhang, L., Lei, S., Mu, X., & Ji, Y. (2019) · Chinese Medical Sciences Journal · doi:10.24920/003487 · Cited by 2

An electroporation platform for Erlotinib resistance screening in living non-small cell lung cancer (NSCLC) cells

Yan, Z., Hui, T. H., Fong, A. H.-W., Shao, X., Cho, W. C. S., Ngan, K. C., Yip, T. C., & Lin, Y. (2017) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/aa99e9 · Cited by 2

Techniques for maximizing the performance of molecular pathology testing: responsibilities of all pathologists

Uzun, E., & Sarıoğlu, S. (2017) · Turkish Journal of Pathology · doi:10.5146/tjpath.2017.01420 · Cited by 2

First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?

Passaro, A., Spitaleri, G., & de Marinis, F. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1210007 · Cited by 2

Cáncer de pulmón no microcítico

Expósito, F., González, J. L. L., Castillo, C., Losada, C. N., & Soto, M. Á.-M. (2017) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2017.04.001 · Cited by 1

Thérapeutiques ciblées dans les tumeurs solides de l’enfant et de l’adolescent

Abbou, S. D., & Valteau‐Couanet, D. (2016) · ONCOLOGIE · doi:10.1007/s10269-016-2670-4 · Cited by 1

Ketogenic Diet as Adjunctive Therapy for Malignant Brain Cancer

Scheck, A. C., & Syed, N. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780197501207.003.0015 · Cited by 1

New targeted therapies for non-small cell lung cancer

Lee, E. H., Kwak, S. H., Kim, C. Y., Gwon, H. R., Kim, E. Y., & Chang, Y. S. (2023) · Journal of Korean Medical Association · doi:10.5124/jkma.2023.66.3.180 · Cited by 1

Non-canonical Activation of Receptor Tyrosine Kinases in Cancer Progression

Sakurai, H. (2017) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.16-00229-4 · Cited by 1

Molecular Pathology of Lung Tumors

Popper, H. (2021) · Springer eBooks · doi:10.1007/978-3-030-55743-0_19 · Cited by 1

Identifying the genetic basis of variation in cell behaviour in human iPS cell lines from healthy donorsPreprint

Vigilante, A., Laddach, A., Moens, N., Meleckyte, R., Leha, A., Ghahramani, A., Culley, O. J., Kathuria, A., Hurling, C., Vickers, A., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/285627

Non-Small Cell Lung Cancer: Common Types

Rampinelli, C., Passaro, A., Casiraghi, M., & Fanciullo, C. (2020) · Cancer dissemination pathways · doi:10.1007/978-3-030-27233-3_3 · Cited by 2

Gene expression profiles of some prognostic markers in a human breast cell line (MCF7) exposed to Curcumin nanoparticles and nanocapsulesPreprint

Shaker, E. S., Nasr, G. M., & Moawad, M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.04.474885

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

Barnes, T. A., O'Kane, G. M., Vincent, M. D., & Leighl, N. B. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00113 · Cited by 61

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer

Pirker, R. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000260 · Cited by 27

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer

Wright, N. A., & Goss, G. D. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.06.01 · Cited by 95

Resistance mechanisms to third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in lung adenocarcinoma cells harboring the EGFR-T790M mutation

Nakatani, K., Yamaoka, T., Ohmori, T., Ohba, M., Fujita, K., Taki, I., Kamei, D., Iawai, S., & Sasaki, Y. (2018) · Proceedings for Annual Meeting of The Japanese Pharmacological Society · doi:10.1254/jpssuppl.wcp2018.0_po4-6-22

Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs)

Mountzios, G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.10.04 · Cited by 18